Research
Over the following pages we will be highlighting some current studies that are open for recruitment.
LANTana: RECRUITING
Patients with neuroendocrine tumours (NETs).
Assessing feasibility of ASTX727 to re-express SSR2 in those with negative/low uptake [68Ga]Ga-DOTA-TATE-PET/CT who would be otherwise ineligible for protein radionucleotide receptor therapy.
Key Eligibility:
Histologic diagnosis of NET (Ki67 <55%) No or low uptake on [68Ga]Ga-DOTATATE- PET/CT ≥1 prior therapy
CLICK HERE to read more on the clinicaltrials.gov website.
Referrals for this study will be through your specialist clinical team.
www.neuroendocrinecancer.org.uk
Made with FlippingBook interactive PDF creator